ANVS

Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Annovis Bio Inc revenue for the last quarter amounts to -7.43M USD, increased 69.45 % YoY.

Annovis Bio Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Annovis Bio Inc (ANVS) has 8 emplpoyees as of December 17 2025.

Today ANVS has the market capitalization of 104.02M USD.